Targeting the TGF-β1 pathway for normalization of chronic liver diseases
Version 1

The transforming growth factor (TGF)-β has been identified as a master regulator of liver fibrogenesis. Thus, targeting TGF-β1 pathway might modulate chronic liver disease (CLD) development and/or progression in murine model. Galunisertib (Ly2157299), already in clinical studies phase II, is an oral small molecule targeting TGF-β type I receptor (ALK-5).

SEEK ID: https://seek.lisym.org/presentations/13?version=1

Filename: LiSym_Dresden_Julia Werle_2.pdf 

Format: PDF document

Size: 8.06 MB

help Creators and Submitter
Creator
Additional credit

Julia Werle

Submitter
Activity

Views: 2704   Downloads: 5

Created: 18th May 2017 at 13:00

Last updated: 4th Jan 2018 at 16:02

help Tags

This item has not yet been tagged.

help Attributions

None

Version History

Version 1 (earliest) Created 18th May 2017 at 13:00 by Seddik Hammad

No revision comments

Powered by
(v.1.15.2)
Copyright © 2008 - 2024 The University of Manchester and HITS gGmbH